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Abstract 
Background: In patients with non-small cell lung cancer (NSCLC), a higher response rate can be achieved with epidermal growth factor 
receptor-tyrosine kinase inhibitors (EGFR-TKIs) when selection for therapy is guided by mutation analysis or gene amplification. 
However, both tests are complex and require tumour tissue. Simple methods to identify responders prior to EGFR-TKI treatment are 
urgently needed. This study aimed to define the relation between serum sEGFR levels, carcinoembryonic antigen (CEA) and survival in 
NSCLC patients treated with EGFR-TKIs.  
Methods: Patients with stage III/IV NSCLC treated with gefitinib or erlotinib between July 2002 and December 2005 were reviewed. 
Levels of serum soluble EGFR (sEGFR) were determined by a sandwich quantitative enzyme-linked immunosorbent assay. A 
chemiluminescence immunoassay was used for CEA. The relation between sEGFR and survival was investigated.  
Results: One hundred and two NSCLC patients, mainly stage IV (80%), were identified. Mean sEGFR at baseline was 55.9 μg/l (range 
35.3–74.5 μg/l). The median CEA level was 11.1 μg/l (range <1.0–2938.0 μg/l). Median overall survival was 5.2 months (range 1–52 
months). Decreasing log CEA values (HR 1.51, 95% CI 1.11–2.04, multivariate analysis) and increasing sEGFR values (HR 0.96, 95% 
CI 0.93–0.99, multivariate analysis) were both independently associated with prolonged survival. Higher levels of pre-treatment sEGFR 
were associated with lower risk of progressive disease within three months (p=0.04). 
Conclusions: Both baseline sEGFR and CEA levels in NSCLC patients receiving EGFR-TKIs showed a significant correlation with 
survival. To distinguish whether these factors have a predictive or a prognostic value, validation is warranted in an independent patient 
series containing a control arm without EGFR-TKI treatment.  
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Background 
The epidermal growth factor receptor (EGFR) is a receptor 
tyrosine kinase that is abnormally activated in different types of 
epithelial malignancies. A constitutively activated EGFR can 
lead to malignant transformation of the cell. It was shown 20 
years ago that blocking of the EGFR could inhibit cell 
proliferation in these transformed cells [1]. Since these first 
observations various drugs have been developed that target 
either the extra-cellular domain or the intracellular tyrosine 
kinase domain of the EGFR. Especially, drugs of the latter 
category, small molecule adenosine triphosphate-competitive 
inhibitors of the receptor’s tyrosine kinase (EGFR-TKIs), such 
as erlotinib and gefitinib, have proven their efficacy in the 
treatment of non-small cell lung cancer (NSCLC) [2–4]. 
However, response rates of erlotinib and gefitinib in unselected 
patient populations are low, and selection of patients is 
warranted to increase response rates to a more satisfying level. 
A response rate of 30% can be achieved when selection of 
patients is based on their phenotype (female gender, non-
smoking status, Asian origin, adeno- or bronchioloalveolar 
carcinoma) [5–9]. This can be increased up to 70% when 
selection is based on EGFR mutation or FISH analysis [10–18]. 
However, for these assays availability of tumour tissue is a 
prerequisite, while this is frequently not at hand in advanced 
NSCLC. More simple and accessible predictors of response are 
warranted. 
Recently, soluble EGFR (sEGFR) was recognized as a potential 
screening tool for epithelial cancer [19,20]. SEGFR is a 
proteolytically cleaved form of the extra-cellular domain of the 
EGFR and can be measured directly in the serum [21,22]. The 
plausibility of sEGFR being a surrogate marker for response to 
treatment with an EGFR-TKI is based on the hypothesis that the 
level of sEGFR reflects the absolute number of activated 
receptors, susceptible to inhibition [23]. A decrease in sEGFR 
during treatment with gefitinib has been recognized to correlate 
with disease control in patients with NSCLC [24]. However, the 
role of baseline sEGFR as a predictive marker for response and 
survival in clinical practice is still uncertain.  
The conventional tumour marker  carcinoembryogenic antigen 
(CEA) is a member of the immunoglobulin supergene family, a 
cell surface adhesion protein, and it is thought to play a role in 
cell-to-cell adhesion. Since there is evidence that elevated pre-
treatment levels of CEA are also predictive for response and 
outcome after the EGFR-TKI treatment, independent of
histological subtype, we decided to study both baseline sEGFR 
and CEA levels in relation to survival after the EGFR-TKI 
treatment [25].  
 
Patients and methods 
Patients selection and study design
Between July 2002 and December 2005, patients with 
advanced non-small cell lung cancer, not responding to 
conventional chemotherapy or unable to receive chemotherapy 
due to poor medical condition, were offered treatment with 
gefitinib (Iressa®) or erlotinib (Tarceva®) as part of the 
Expanded Access Programme, on a compassionate use basis. 
Consecutive patients who were treated for more than 14 days 
were identified and enrolled in this study if pre-treatment serum 
was available for sEGFR analysis. The final sample size was 
determined according to the number of available patient serum 
samples.  Hospital records were retrospectively reviewed for 
age, gender, race, smoking status, histological subtype, stage, 
side effects and toxicity of the EGFR-TKI treatment and best 
overall response to EGFR-TKI. Informed consent was obtained 
from all patients. For design and report of this study, the 
REMARK guidelines were followed [26]. 
Patients receiving gefitinib were treated with a daily dose of 250 
mg. In case of unacceptable or severe (grades 3–4) toxicity, the 
treatment with gefitinib was interrupted. Erlotinib was 
administered in daily doses of 150 mg. Dose changes of 50 mg 
were possible in case of unacceptable toxicity. Adverse events 
were assessed according to the National Cancer Institute—
Common Toxicity Criteria version 2. Treatment of gefitinib or 
erlotinib was continued until disease progression or the 
occurrence of a serious adverse event.  
Assessment of sEGFR and CEA levels 
Blood samples had to be collected within two months before 
start of treatment with EGFR-TKIs. Serum was stored at −30˚C. 
Concentration levels of the EGFR-extra-cellular-binding domain 
were determined by a sandwich quantitative enzyme-linked 
immunosorbent assay (EGFR Microtiter ELISA; Oncogene 
Science, Cambridge, MA) according to the manufacturer’s 
instructions. The normal range is 45–78 μg/l as described 
previously [27]. Carcinoembryonic antigen was measured on



















the E170 analyzer, which is based on chemiluminescent 
immunometric technology (Roche Diagnostics, Mannheim, 
Germany) [28]. 
Response assessment and statistical analysis 
Correlation among sEGFR, CEA and age were studied using 
Pearson correlation analysis. Associations between sEGFR, 
CEA, gender, stage (III, IV), smoking status (smoker, non-
smoker) and histology (adenocarcinoma, squamous cell 
carcinoma and large cell undifferentiated) were investigated by 
means of the Student’s t test or generalized linear regression.  
Overall survival was calculated using the Kaplan–Meier method, 
from the first day of treatment with the EGFR-TKI to the date of 
death. Differences in survival between subgroups of patients 
were determined using the log rank test. Univariate analysis 
(Cox proportional hazard regression analysis) was used to 
detect associations between sEGFR and CEA levels and 
survival. Furthermore, age, gender, smoking status, tumour 
stage, histology and treatment drug were investigated. The 
assumptions of linearity and proportional hazards for sEGFR 
and CEA were checked by means of Martingale residuals and 
scaled Schoenfeld residuals [29,30]. Continuous variables (age, 
sEGFR and logCEA) were tested for possible non-linear 
associations (violence of the proportional hazards 
assumptions).  To present Kaplan–Meier plots for sEGFR and 
logCEA,  a cut-off was used to divide these factors into two 
separate groups (i.e. high vs low). A spline function through the 
Martingale residuals of sEGFR and logCEA was used to 
determine possible cut-off values, i.e., the concentration of 
sEGFR or CEA, where the line crossed through zero of the 
Martingale residuals, was used as the cut-off.  Variables 
achieving a probability value of less than 0.10 in the univariate 
analysis as well as pre-operative factors considered relevant in 
the available literature [31–33] were introduced in a multivariate 
stepwise proportional hazard analysis to identify variables 
significantly associated with survival. p-values < 0.05 were 
considered statistically significant. 
Response evaluation was performed using computed 
tomography (CT) according to the Response Evaluation Criteria 
In Solid Tumors (RECIST) [34]. Response measurement at 
fixed intervals was not available for every patient. The 
occurrence of early progressive disease (PD) (within three 
months) was investigated to analyze the relation between (non-) 
response and sEGFR and/or CEA levels. Associations between 
high or low sEGFR and/or CEA levels, and early occurrence of 
PD were tested using non-parametric tests. For this purpose, 




Over a 3.5 years period, 145 patients with advanced non-small 
cell lung cancer were treated with gefitinib or erlotinib. Of these, 
102 patients with available serum samples were eligible, 54 
men and 48 women, with a mean age of 59 years (95% CI 57–
61 years). Patients’ characteristics are shown in Table 1. The 
median follow-up was 161 days (range 17–1581 days). EGFR 
mutation status was assessed in 13 patients, of whom six 
patients had mutations, three patients had a mutation in exon 
19, one patient in exon 20 and two patients in exon 21. Sixty-
seven patients were treated with gefitinib and 35 patients were 
treated with erlotinib. The median duration of treatment with 
gefitinib was 69 days (range 14–1259 days) and with erlotinib 
78 days (range 15–814 days).  
Baseline sEGFR levels were available for all 102 patients and 
showed a Gaussian distribution. The mean sEGFR level at 
baseline was 55.9 μg/l (SD 8.9). Given the normal range 
provided by the manufacturer of the test (48–72 μg/l), 23% of 
patients had decreased sEGFR levels. Patients with a 
squamous cell tumour had significant lower values of sEGFR 
compared to patients with tumours of the undifferentiated cell 
type (p=0.0267); sEGFR levels of patients with adenocarcinoma 
were found in between. Age was the only patient’s characteristic 
that significantly inversely correlated with sEGFR (correlation 
−0.31, p=0.0014). No significant associations were detected for 
sEGFR levels with gender, smoking status or tumour stage. 
Baseline CEA values were available for 100 patients. CEA 
values did not follow a normal distribution. The median serum 
CEA value overall was 11.1 μg/l (range <1.0–2938.0 μg/l). 
Using the internationally accepted upper limit of normal of 6.5 
μg/l for smokers and 5.0 μg/l for non-smokers, 67 patients 
(67%) had elevated CEA levels.  Because of the skewed 
distribution of CEA, further analyses were performed using the 
logarithm of CEA (log CEA, mean 1.17, SD 0.75). Log CEA 
levels were significantly lower for stage III patients (p=0.01197) 
and for squamous cell compared to undifferentiated large cell 
type (p=0.0359). Values of patients with adenocarcinoma were 
very close to values of patients with tumours of the 
undifferentiated large cell type. For age, gender or level of 
sEGFR no association with log CEA was found. 
When continuous variables (age, sEGFR and logCEA) were 
checked for possible non-linear associations, none were found 



















Table 1: Patient and tumour characteristics (n=102). 
 
to be significant. Consequently, the continuous variables could 
be included as linear continuous parameters. 
The median overall survival was 5.2 months (range 0.6–52.0 
months). In an univariate analysis, smoking status and sEGFR 
were shown to be significant prognostic factors (Table 2, 
p=0.001 and p=0.018, respectively). Cut-off values for sEGFR 
and log CEA were found at 55 μg/l and 1.1 (corresponding with
CEA= 12.6 µg/l), respectively. Patients with sEGFR levels 
above 55 μg/l had a significantly longer overall survival (Figure 
1a, log rank p=0.033), while patients with a log CEA level below 
1.1 showed a trend toward longer overall survival (Figure 1b, 
log rank p=0.06). In a multivariate overall survival model, 
sEGFR and log CEA, in addition to smoking, proved to be 
independently associated with survival (Table 3). 
 



















Table 2: Univariate analysis in patients with advanced NSCLC before treatment with EGFR-TKIs 
Discussion  
In the present study, baseline sEGFR and CEA levels were 
measured in patients with advanced NSCLC before the 
treatment with erlotinib or gefitinib. Our results suggest that 
higher sEGFR and lower CEA levels are related to prolonged 
survival in patients receiving EGFR-TKI treatment, indicating 
that the combination of sEGFR and CEA could be valuable for 
the selection of patients for the EGFR-TKI treatment. 
Carcinoembryonic antigen is a member of the immunoglobulin 
superfamily and plays a role in cell-to-cell adhesion [35]. When 
CEA is over-expressed on the cell surface, it is thought to play a 
role in tumourigenesis by disruption of cell polarity, inhibition of
apoptosis (anoikis) and inhibition of cell differentiation [36–38]. 
The over-expression of CEA has been found to be present in 
many types of carcinomas [39]. In non-small cell lung cancer, 
an elevated serum CEA level is generally considered to be a 
negative prognostic factor especially for adenocarcinoma [40]. 
Therefore, the finding of Okamoto et al. that a high CEA was 
predictive for good response to the EGFR-TKI treatment, 
independent of histology, was highly surprising [41]. They did 
not have an explaining mechanism of action for this 
phenomenon, but hypothesized that an anti-apoptotic signal of 
the (mutant) EGFR may somehow elevate the expression level 
of CEA protein. In this study, we could not confirm the results of 
Okamoto et al. In contrast, we found that a low CEA level was 
independently associated with better outcome after the




















Figure 1: Overall survival by sEGFR and log CEA. 
treatment with EGFR-TKIs. This is in accordance with the 
previous findings of the negative prognostic ability of CEA [42]. 
Our results suggest that serum levels of CEA and sEGFR are 
not (directly) regulated by the same mechanism of action, since 
both remained significant upon multivariate analysis. Only few 
studies are available on sEGFR in non-small cell lung cancer, 
mostly concerning the comparison of sEGFR levels in healthy 
individuals and lung cancer patients. Two studies found that 
patients with NSCLC had lower baseline sEGFR levels 
compared to healthy controls [43,44], whereas others did not 
detect significant differences [45,46]. However, up till now, there 
are no data available on the prognostic value of serum sEGFR 
for NSCLC. Only one study investigated changes in the sEGFR 
levels during the EGFR-TKI treatment as a predictive marker for 
response to these inhibitors [47]. Responders showed a 
decrease in the sEGFR levels at time of best response 
compared to baseline level, whereas non-responders showed 
an increase. A difference of −3.6 μg/l as a cut-off was found to 
identify responders at time of best response. However, a 
meaningful cut-off level for (pre-treatment) baseline levels could 




















Table 3: Multivariate overall survival model in patients with advanced NSCLC before treatment with EGFR-TKIs: results of the Cox proportional 
hazard regression analysis 
 
 
not be established, and therefore, sEGFR was not considered 
to be a useful predictive marker. Unfortunately, in our study, 
serum samples drawn during treatment were not available, and 
we therefore could not validate these results. 
The one-armed design and retrospective nature of our study 
prohibit clear differentiation between the prognostic and the 
predictive values of sEGFR and CEA. Interpretation of response 
data (progressive disease) remains difficult, but these data 
suggest at least some predictive potential for sEGFR. Higher 
levels of pre-treatment sEGFR in patients treated with EGFR-
TKIs were associated with lower risk of progressive disease 
within three months.  
The prognosis of advanced NSCLC after failure of second or 
third line treatment is generally only weeks to months. Intensive 
follow-up with additional imaging during this period is 
undesirable, and further efforts to evaluate response or 
progression-free survival are meaningless. The distinction 
between the prognostic value and the predictive value of these 
two markers remains important, since their potential predictive 
value may contribute to an adequate patient selection for 
expensive EGFR-TKI treatment. Therefore, validation of this 
potential predictive value in a prospective controlled (two-
armed) study is warranted. 
In conclusion, these results suggest that sEGFR and CEA are 
the markers of survival in patients treated with EGFR-TKIs. The 
potential predictive value of sEGFR needs confirmation in a 
prospective controlled trial. 
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